β1 Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues
Journal of Cardiovascular Development and Disease · 10.09.2023 · 10 (9) · 390
DOI: 10.3390/jcdd10090390 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 10.09.2023. Verfasst von Akane Kawai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, National Defense Medical College, Tokorozawa 359-8513, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant-in-Aid for Scientific Research, Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
A wide range of anti-myocardial autoantibodies have been reported since the 1970s. Among them, autoantibodies against the β1-adrenergic receptor (β1AR-AAb) have been the most thoroughly investigated, especially in dilated cardiomyopathy (DCM). Β1AR-Aabs have agonist effects inducing desensitization of β1AR, cardiomyocyte apoptosis, and sustained calcium influx which lead to cardiac dysfunction and arrhythmias. Β1AR-Aab has been reported to be detected in approximately 40% of patients with DCM, and the presence of the antibody has been associated with worse clinical outcomes. The removal of anti-myocardial autoantibodies including β1AR-AAb by immunoadsorption is beneficial for the improvement of cardiac function for DCM patients. However, several studies have suggested that its efficacy depended on the removal of AAbs belonging to the IgG3 subclass, not total IgG. IgG subclasses differ in the structure of the Fc region, suggesting that the mechanism of action of β1AR-AAb differs depending on the IgG subclasses. Our previous clinical research demonstrated that the patients with β1AR-AAb better responded to β-blocker therapy, but the following studies found that its response also differed among IgG subclasses. Further studies are needed to elucidate the possible pathogenic role of IgG subclasses of β1AR-AAbs in DCM, and the broad spectrum of cardiovascular diseases including HF with preserved ejection fraction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, National Defense Medical College, Tokorozawa 359-8513, Japan.
- Department of Intensive Care, National Defense Medical College, Tokorozawa 359-8513, Japan.
ORCID-Profile: Akane Kawai, Yuji Nagatomo, Takumi Toya
Förderung
- Grant-in-Aid for Scientific Research
- Society for the Promotion of Science (JSPS)
Zitieren
APA
Kawai, A., Nagatomo, Y., Yukino-Iwashita, M., Nakazawa, R., Taruoka, A., Yumita, Y., Takefuji, A., Yasuda, R., Toya, T., Ikegami, Y., Masaki, N., Ido, Y., & Adachi, T. (2023). β1 Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues. Journal of Cardiovascular Development and Disease, 10(9), 390. https://doi.org/10.3390/jcdd10090390
Vancouver
Kawai A, Nagatomo Y, Yukino-Iwashita M, Nakazawa R, Taruoka A, Yumita Y, et al. β1 Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues. Journal of Cardiovascular Development and Disease. 2023;10(9):390. doi:10.3390/jcdd10090390
BibTeX
@article{Kawai2023,
author = {Kawai, Akane and Nagatomo, Yuji and Yukino-Iwashita, Midori and Nakazawa, Ryota and Taruoka, Akira and Yumita, Yusuke and Takefuji, Asako and Yasuda, Risako and Toya, Takumi and Ikegami, Yukinori and Masaki, Nobuyuki and Ido, Yasuo and Adachi, Takeshi},
title = {β1 Adrenergic Receptor Autoantibodies and IgG Subclasses: Current Status and Unsolved Issues},
journal = {Journal of Cardiovascular Development and Disease},
year = {2023},
volume = {10},
number = {9},
pages = {390},
doi = {10.3390/jcdd10090390}
}
EUVIMED